Novartis Exelon
Executive Summary
Firm clarifies that two-week or longer intervals between dose increases of Alzheimer's agent in postmarketing has resulted in "improved tolerability as evident from fewer GI complaints than seen in pivotal studies." The company previously said that rivastigmine postmarketing nausea/vomiting reports have been consistent with rates seen in clinical trials (1"The Pink Sheet" Feb. 5, p. 24)
You may also be interested in...
Novartis Exelon Labeling Update Reflects Report Of Esophageal Rupture
Novartis' revised labeling for the Alzheimer's agent Exelon (rivastigmine) directs that therapy should be reinitiated at the lowest daily dose following treatment interruption in order to reduce the risk of severe vomiting and esophageal rupture.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials